across

Salcaprozate sodium (SNAC), an oral absorption promoter, enhances passive transcellular permeation through small intestinal epithelia, making it a potent delivery agent for oral heparin and insulin by increasing lipophilicity via non-covalent macromolecule complexation.

Oxaliplatin (L-OHP) is a DNA alkylating agent and DNA synthesis inhibitor. Oxaliplatin induces cellular autophagy and DNA cross-linking damage, thereby inhibiting DNA replication and transcription and leading to cell death. Oxaliplatin is unstable in chlorine-containing systems; dissolution in saline or PBS is not recommended. A 5% glucose/dextrose solution can be used to prepare the solution for in vivo administration.

6-Aminonicotinamide (6-AN) is a well-established inhibitor of the NADP+-dependent enzyme.

PXS-5153A is an effective, selective, and fast-acting inhibitor of lysyl oxidase like 2/3 enzymes with enzymatic activity almost entirely blocked within 15 minutes. PXS-5153A could reduce crosslinks and ameliorates fibrosis.

SIA Crosslinker is a non-cleavable ADC linker designed for synthesizing antibody-drug conjugates (ADCs)[1].

UAA crosslinker 1 hydrochloride is an amber codon used to incorporate non-canonical amino acids (ncAAs) into proteins in vivo by leveraging the promiscuous activity of specific wildtype and engineered aminoacyl-tRNA synthetases [1].

UAA crosslinker 1 hydrochloride is an Amber codon-activating agent used for incorporating non-canonical amino acids (ncAAs) into proteins in vivo by leveraging the promiscuous activity of specific wildtype and engineered aminoacyl-tRNA synthetases[1].

SBA crosslinker is a sulfhydryl and amino reactive heterobifunctional protein crosslinking reagent. SBA protein crosslinker is non-cleavable and is among the shortest amine and sulfhydryl reactive crosslinking reagents known with a spacer arm length of on

DNA crosslinker 6 (compound 1) is an anti-mitotic agent known for its strong binding affinity to AT-DNA and inhibition of AT-hook 1 binding to DNA (IC50=0.03 µM). Additionally, it exhibits anti-protozoal activity, effectively inhibiting T. brucei with an EC50 of 0.83 µM.

Sulfo-SIA Crosslinker is a non-cleavable, heterobifunctional protein crosslinker. Sulfo-SIA Crosslinker is useful in making antibody-drug conjugates.

DNA Crosslinker 1 (dihydrochloride) serves as a potent binder for the DNA minor groove, exhibiting a DNA binding affinity (ΔTm) of 1.1°C. This compound is utilized in research focused on anticancer therapies [1].

DNA crosslinker 2 (dihydrochloride) is a potent minor groove binder with a ΔTm of 1.2 °C, indicating strong DNA binding affinity. It exhibits inhibitory activity against cancer cell lines NCI-H460, A2780, and MCF-7, making it relevant for anticancer research [1].

DNA Crosslinker 3 (dihydrochloride) (Compound 1) is a potent minor groove binder, exhibiting a DNA binding affinity (ΔTm) of 1.4°C, and serves as a valuable tool in anticancer research [1].

DNA Crosslinker 4 (dihydrochloride) is a potent binder of the DNA minor groove with inhibitory effects on cancer cell lines NCI-H460, A2780, and MCF-7. It is utilized in research for anticancer applications [1].

TIC10 (ONC-201) inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.

Ionomycin is a calcium ion carrier and an antibiotic that binds to calcium ions (Ca2+). The main function of Ionomycin is to induce cellular responses by increasing the intracellular calcium ion concentration. In experiments, Ionomycin is typically used to activate calcium-dependent processes, such as apoptosis and enzyme activity.

Agomelatine (L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors (Kis: 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2), and Agomelatine (S-20098). L(+)-Tartaric acid also functions as a selective 5-HT2C receptor antagonist (pKis: 6.4 and 6.2 at native porcine and cloned human 5-HT2C receptors), actively supporting research into melatonergic signaling pathways, receptor-mediated regulation, and novel psychiatric therapeutics by enabling precise modulation of circadian and serotonergic systems in cellular models to improve neuropharmacological understanding and experimental reproducibility across neuroscientific and clinical translational studies.

CFM-2, a potent and selective non-competitive antagonist of AMPAR (AMPAR), exhibits anticonvulsant activity across various seizure models.

MEG hemisulfate (Mercaptoethylguanidine hemisulfate) acts as a highly potent and selective suppressor of inducible NO synthase (iNOS), demonstrating EC50 values of 11.5 μM for iNOS, 110 μM for ecNOS, and 60 μM for bNOS in tissue homogenates. It is notably effective as a peroxynitrite scavenger and blocks peroxynitrite-triggered oxidative mechanisms. Furthermore, this compound offers protective benefits across various experimental inflammation prototypes, such as ischemia/reperfusion injury, hemorrhagic shock, periodontitis, inflammatory bowel disease, and both endotoxic and septic shock.

Repinotan HCl (Bay-x-3702) is an orally active, selective and potent 5-HT1A receptor agonist across the blood-brain barrier and is an aminomethylbenzidine derivative.Repinotan HCl has potent neuroprotective effects and can be used in studies of ischemic stroke and traumatic brain injury.

Milvexian (BMS-986177/JNJ-70033093) is an orally bioavailable, small-molecule, reversible, and direct antagonist of Factor XIa (FXIa). It exhibits potent inhibitory activity across species, with Ki values of 0.11 nM for human, 0.38 nM for rabbit, and 0.64 nM for dog. By targeting FXIa, Milvexian selectively inhibits the intrinsic pathway of the coagulation cascade. It demonstrates robust antithrombotic efficacy in various in vitro and in vivo models while maintaining a favorable safety profile regarding bleeding risk. It is a critical tool for investigating novel anticoagulant strategies in thrombosis and cardiovascular research.

C-Myc Inhibitor 7, serving as both a c-Myc inhibitor and a multi-target protein degrader, effectively degrades proteins c-MYC, CK1α, GSPT1, and IKZF1/2/3 across various tumor cell types. It holds potential for research into diseases associated with high c-Myc expression, including cancer, cardiovascular and cerebrovascular conditions, and viral infections.

LUF6096 (CF-602) is a potent allosteric enhancer of the adenosine A3 receptor, exhibiting the capability to enhance agonist binding allosterically while demonstrating low orthosteric affinity across adenosine receptors. It displays protective effects in myocardial ischemia/reperfusion injury.

Quinidine hydrochloride monohydrate is an optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. It prolongs cellular action potential and decreases automaticity. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.